Latest research on Prolia

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.

Prolia indications

Recent studies have demonstrated the effectiveness of denosumab (Prolia, Amgen, Inc., Thousand Oaks, California, United States), an anti-RANKL antibody, in the treatment of recurrent or unresectable giant cell tumors. [source, 2014]
In terms of cancer patients or survivors, this means we are reading more about potential relationships of Vitamin D deficiency and aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) as well as cancer and cancer mortality, impaired bone health (osteoporosis or osteomalacia), and adverse effects with administration of bisphosphonates or denosumab (Prolia, Xgeva). [source, 2012]